- Truist resumed coverage on September 23, 2026.
- Rating: Buy.
- Price target: $285.
- Truist resumed analyst coverage of Axsome Therapeutics with a Buy rating and a $285 price target.
Truist resumed coverage of Axsome Therapeutics (AXSM) with a Buy rating and a $285 price target. The resumption signals a positive view on the stock's prospects.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.